AIM ImmunoTech Reports Positive Mid-Year Results for Ampligen in Pancreatic Cancer Trial.

AIM ImmunoTech has reported encouraging mid-year results from its Phase 2 clinical trial of Ampligen in combination with Imfinzi for pancreatic cancer treatment. The trial, DURIPANC, has shown no significant toxicity and positive progression-free survival and overall survival metrics. Approximately 21% of patients have maintained progression-free survival beyond six months, with another 21% yet to see disease progression. The majority have experienced overall survival longer than six months. Based on analyst forecasts, AIM ImmunoTech's average target price is $150, implying a 1,685.71% upside from the current price.

AIM ImmunoTech Inc. (NYSE American: AIM) has released positive mid-year data from its Phase 2 clinical trial, DURIPANC, evaluating the combination of Ampligen® (rintatolimod) and AstraZeneca's Imfinzi® (durvalumab) for the treatment of metastatic pancreatic cancer patients. The trial, conducted in collaboration with AstraZeneca and Erasmus Medical Center, has enrolled 14 out of 25 planned subjects, showcasing encouraging interim results.

The mid-year report highlights no significant toxicity among post-chemotherapy patients, with approximately 21% of patients experiencing progression-free survival (PFS) exceeding six months and another 21% not yet progressed. Additionally, 64% of eligible patients have achieved overall survival (OS) beyond six months. These results are particularly noteworthy as pancreatic cancer typically shows minimal response to immunotherapy approaches, and the standard treatment pathway involving FOLFIRINOX chemotherapy often sees limited benefit from maintenance or second-line therapies.

The early safety profile and survival metrics from the DURIPANC study appear to outperform typical expectations for this disease stage. The study builds upon AIM's previous work with Ampligen as a monotherapy, which has already produced several peer-reviewed publications suggesting efficacy. AIM has secured intellectual property protection through a U.S. patent extending to 2039 and orphan drug designations in both the U.S. and EU for Ampligen in pancreatic cancer treatment, creating potential long-term commercial value if efficacy is confirmed.

Analysts have noted the promising interim data and have forecasted an average target price of $150 for AIM ImmunoTech, implying a significant upside potential of 1,685.71% from the current price. The company's CEO, Thomas K. Equels, expressed optimism about the potential benefits of combining Ampligen's innate immune activation with Imfinzi's checkpoint inhibition in pancreatic cancer maintenance therapy.

The DURIPANC study is part of AIM's ongoing effort to develop Ampligen for the treatment of pancreatic cancer, with more than 50 patients having received treatment as part of a Dutch government-approved Compassionate Use/Early Access Program at Erasmus Medical Center. The study's primary objective is to assess the clinical benefit rate of the combination therapy, with secondary objectives including assessing OS, PFS, and initiating immune-monitoring using available tissue biopsies and peripheral immune profiling.

The interim results from the DURIPANC study represent a potentially significant development in pancreatic cancer treatment, one of the most challenging and lethal cancer types. Further analysis and follow-up are essential to determine the biological activity and the durability of response, as well as to identify which patients are most likely to benefit from the combination treatment.

References:
[1] https://www.stocktitan.net/news/AIM/aim-immuno-tech-reports-positive-mid-year-safety-and-efficacy-data-nbszbkp0gfmz.html
[2] https://www.marketscreener.com/news/aim-immunotech-reports-positive-mid-year-safety-and-efficacy-data-from-phase-2-study-evaluating-ampl-ce7c5fd8dc81f32c